ProMetic Life, Abraxis BioScience to jointly commercialize prion capture technology

The Canadian Press ~ The News
Send to a friend

Send this article to a friend.

MONTREAL - ProMetic Life Sciences Inc. (TSX:PLI) has a new agreement to collaborate with Abraxis BioScience, Inc. (NASDAQ:ABII) on commercializing ProMetic's prion capture technology.
Prions are a naturally occurring form of protein that have been linked to some degenerative brain diseases, including Mad Cow disease and Creutzfeldt-Jacob disease.
ProMetic announced Tuesday that the two companies will equally share in the costs and financial rewards from their commercialization efforts. It didn't disclose an estimate on what those costs and rewards would be.
The agreement with Abraxis is complementary to ProMetic's partnership with MacoPharma SA for the commercialization of the P-Capt prion capture filter and with Octapharma AG for OctaplasLG prion-reduced plasma for transfusions, the Montreal-based company said.

Organizations: ProMetic Life Sciences Inc., Abraxis BioScience, Inc., TSX MacoPharma SA Octapharma AG for OctaplasLG

Geographic location: MONTREAL

  • 1
  • 2
  • 3
  • 4
  • 5

Thanks for voting!

Top of page